The Economic Times

Cipla expects sequential recovery in North America on new product launches despite tariff uncertainty

Cipla reported a 39% drop in net profit to 789 crore for the June quarter due to weakness in its North America business and margin compression, despite posting record revenue of 7,119 crore. EBITDA declined 33%, with margins narrowing significantly. Growth was driven by strong performance in India, Africa, and emerging markets, with the domestic business hitting an all-time high. The company remains focused on new product launches, including respiratory and peptide segments, and expects a recovery in the US business led by Ventolin supplies.